

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering  
Cancer Center

[About Us](#)  
[Sloan Kettering Institute](#)

IMMUNOLOGY PROGRAM

[Research](#)

## The Michael Glickman Lab

[Education & Training](#)

[Immunology Program](#)  
[News & Events](#)

**Research**  
[Open Positions](#)



Michael S. Glickman, MD

---


We are broadly interested in the biology of mycobacteria, which include the major human pathogen *M. tuberculosis*, the nonpathogenic model organism *M. smegmatis*, and the cancer biotherapeutic agent BCG.

[View Lab Overview](#) →

## Research Projects

[Molecular Pathogenesis of \*M. tuberculosis\* infection](#)

[DNA Repair and Mutagenesis in Mycobacteria](#)



## Featured News



### [At Work: Infectious Diseases Specialist Michael Glickman](#)

Physician-scientist Michael Glickman cares for cancer patients who have infections. In his laboratory, he aims to understand how infections develop.



### [MSK Scientists Solve One of TB's Deadliest Tricks](#)

Scientists at Memorial Sloan Kettering have pieced together the biochemical mechanism by which the tuberculosis bacterium sneaks past our immune defenses.



### [The ABCs of BCG: Oldest Approved Immunotherapy Gets New Explanation](#)

BCG has been used to treat bladder cancer for more than 30 years. Scientists are still learning how it works.

## Publications Highlights

[Distinctive roles of translesion polymerases DinB1 and DnaE2 in diversification of the mycobacterial genome through substitution and frameshift mutagenesis](#)

P Dupuy, S Ghosh, O Adefisayo, J Buglino, S Shuman, MS Glickman

Nature Communications 13 (1), 4493

[Roles for mycobacterial DinB2 in frameshift and substitution mutagenesis](#)

P Dupuy, S Ghosh, A Fay, O Adefisayo, R Gupta, S Shuman, ...

[View All Publications](#)


## People




## Michael S. Glickman, MD

Physician-scientist Michael Glickman investigates the physiology and pathogenic mechanisms of mycobacteria, including the use of mycobacteria as bacterial cancer therapies.


MD, Columbia University College of Physicians and Surgeons

 [glickmam@mskcc.org](mailto:glickmam@mskcc.org)

Email Address

 [646-888-2368](tel:646-888-2368)

Office Phone



 [View physician profile](#)

Physician profile

### Members

Senior Research Scientist

Assistant Attending  
Physician




Jamie Bean

Assistant Lab Member,  
EIO Cell Bank director


Anna Benjamin

Lab Manager




Shireen Khayat

Graduate Student



Adam Krebs

Graduate Student



Yaprak  
Ozakman

Research Scholar

Gaurav Sankhe

Research Associate

Pablo Santos Molina

MSK Bridge Program  
Scholar



Veronica  
Shields

Administrative Assistant

Lab Alumni  
+

Lab Affiliations  
+

## Get in Touch

✉ [glickmam@mskcc.org](mailto:glickmam@mskcc.org)

Lab Head Email

☎ [646-888-2368](tel:646-888-2368)

Office Phone

☎ [646-422-0502](tel:646-422-0502)

Office Fax



 [646-888-2360](tel:646-888-2360)

Lab Phone

 [646-422-0502](tel:646-422-0502)

Lab Fax

 [\\_ Michael Glickman's Twitter](#)

## Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Michael S. Glickman discloses the following relationships and financial interests:

Fimbrion Therapeutics, Inc.

Professional Services and Activities

Vedanta

Equity; Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

---

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies [here](#). For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [ecoi@mskcc.org](mailto:ecoi@mskcc.org).

[View all disclosures](#) →

### ▾ About Us

[Overview](#)

[Leadership](#)

[Administration](#)

[History](#)

[Contact Us](#)



## ▼ Research

[Overview](#)

[Research programs](#)

[Research labs](#)

[Core facilities & resources](#)

## ▼ Education & Training

[Overview](#)

[Postdoctoral training](#)

[Gerstner Sloan Kettering Graduate School](#)

[Joint graduate programs](#)

[Programs for college & high school students](#)

## ▼ News & Events

[Overview](#)

[Seminars & events](#)

## ▼ Open Positions

[Overview](#)

[Faculty positions](#)

[Postdoctoral positions](#)

---

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility Statement](#)

[Privacy policy](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center